2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists | Journal of Medicinal Chemistry
Scholarly Web-portal
Frontiers | Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia
NameDatabases/all.txt at master · smashew/NameDatabases · GitHub
Andrea Cappelli's Instagram, Twitter & Facebook on IDCrawl
Dr. Rajnish Mehrotra, MD | Seattle, WA | Nephrologist | US News Doctors
British Journal of Haematology: Early View
Frontiers | Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies